AAPL293.83+4.47 (+1.54%) ▲|ABBV250.91-0.74 (-0.29%) ▼|ABT92.23+1.49 (+1.64%) ▲|ACN131.48+7.04 (+5.66%) ▲|ADBE211.32+6.30 (+3.07%) ▲|AMAT653.06-69.95 (-9.67%) ▼|AMD544.39-36.52 (-6.29%) ▼|AMGN361.22-0.91 (-0.25%) ▼|AMT165.42+1.85 (+1.13%) ▲|AMZN241.80+3.46 (+1.45%) ▲|AVGO371.43-6.33 (-1.67%) ▼|AXP348.39+10.14 (+3.00%) ▲|BA218.90+2.43 (+1.12%) ▲|BAC58.38+1.40 (+2.46%) ▲|BKNG182.65+4.41 (+2.48%) ▲|BLK985.83+24.27 (+2.52%) ▲|BMY56.58-1.04 (-1.81%) ▼|BNY146.43+1.82 (+1.26%) ▲|BRK-B501.32+0.93 (+0.19%) ▲|C140.53+0.57 (+0.41%) ▲|CAT995.21-69.69 (-6.54%) ▼|CL92.40+0.72 (+0.78%) ▲|CMCSA23.74-0.82 (-3.32%) ▼|COF204.58+3.96 (+1.97%) ▲|COP103.35-0.61 (-0.58%) ▼|COST923.50-11.97 (-1.28%) ▼|CRM163.73+7.07 (+4.51%) ▲|CSCO116.84-0.62 (-0.53%) ▼|CVS104.72+1.27 (+1.23%) ▲|CVX165.50-0.26 (-0.16%) ▼|DE630.74-3.59 (-0.57%) ▼|DHR193.93+3.45 (+1.81%) ▲|DIS95.92-0.33 (-0.34%) ▼|DUK125.75-0.83 (-0.66%) ▼|EMR140.02-3.14 (-2.19%) ▼|FDX313.91+0.78 (+0.25%) ▲|GD363.33+9.09 (+2.57%) ▲|GE374.49+0.76 (+0.20%) ▲|GEV1,132.37-42.49 (-3.62%) ▼|GILD126.22-0.12 (-0.10%) ▼|GM75.58-1.50 (-1.95%) ▼|GOOG357.81+4.48 (+1.27%) ▲|GOOGL361.01+3.64 (+1.02%) ▲|GS1,021.36+9.99 (+0.99%) ▲|HD351.43-1.26 (-0.36%) ▼|HON221.77-2.13 (-0.95%) ▼|IBM287.23+6.02 (+2.14%) ▲|INTC127.45-12.18 (-8.72%) ▼|INTU268.67+7.67 (+2.94%) ▲|ISRG400.93+3.25 (+0.82%) ▲|JNJ253.86-0.11 (-0.04%) ▼|JPM333.59+6.26 (+1.91%) ▲|KO81.18-0.09 (-0.11%) ▼|LIN533.18+14.24 (+2.74%) ▲|LLY1,193.00-6.43 (-0.54%) ▼|LMT521.83+12.37 (+2.43%) ▲|LOW221.90+1.41 (+0.64%) ▲|LRCX390.26-43.08 (-9.94%) ▼|MA523.26+9.66 (+1.88%) ▲|MCD269.55-0.76 (-0.28%) ▼|MDLZ58.89+1.05 (+1.82%) ▲|MDT79.26+1.03 (+1.32%) ▲|META612.70+49.41 (+8.77%) ▲|MMM160.51-1.40 (-0.86%) ▼|MO71.38-0.58 (-0.80%) ▼|MRK125.68-2.83 (-2.20%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT383.80+10.78 (+2.89%) ▲|MU1,047.70-106.59 (-9.23%) ▼|NEE86.66-1.11 (-1.26%) ▼|NFLX74.04+2.64 (+3.69%) ▲|NKE42.93+1.88 (+4.57%) ▲|NOW106.08+6.80 (+6.84%) ▲|NVDA197.97-2.12 (-1.06%) ▼|ORCL143.09-3.46 (-2.36%) ▼|PEP140.51+5.11 (+3.77%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.05+0.41 (+0.28%) ▲|PLTR126.08+9.41 (+8.07%) ▲|PM177.08-3.83 (-2.12%) ▼|QCOM183.54-1.25 (-0.68%) ▼|RTX191.21+1.48 (+0.78%) ▲|SBUX102.63+0.44 (+0.43%) ▲|SCHW95.91+3.64 (+3.94%) ▲|SO95.32-0.39 (-0.41%) ▼|SPG222.55-1.11 (-0.49%) ▼|T20.40-0.30 (-1.45%) ▼|TMO514.50+13.14 (+2.62%) ▲|TMUS172.78+5.05 (+3.01%) ▲|TSLA425.70+5.10 (+1.21%) ▲|TXN299.34+1.27 (+0.43%) ▲|UBER72.78+0.62 (+0.85%) ▲|UNH427.38+11.75 (+2.83%) ▲|UNP277.01+5.01 (+1.84%) ▲|UPS109.74+2.24 (+2.08%) ▲|USB62.01+1.61 (+2.66%) ▲|V350.40+7.31 (+2.13%) ▲|VZ41.76-0.58 (-1.37%) ▼|WFC85.69+3.05 (+3.68%) ▲|WMT108.83-4.44 (-3.92%) ▼|XOM135.78-0.94 (-0.69%) ▼|AAPL293.83+4.47 (+1.54%) ▲|ABBV250.91-0.74 (-0.29%) ▼|ABT92.23+1.49 (+1.64%) ▲|ACN131.48+7.04 (+5.66%) ▲|ADBE211.32+6.30 (+3.07%) ▲|AMAT653.06-69.95 (-9.67%) ▼|AMD544.39-36.52 (-6.29%) ▼|AMGN361.22-0.91 (-0.25%) ▼|AMT165.42+1.85 (+1.13%) ▲|AMZN241.80+3.46 (+1.45%) ▲|AVGO371.43-6.33 (-1.67%) ▼|AXP348.39+10.14 (+3.00%) ▲|BA218.90+2.43 (+1.12%) ▲|BAC58.38+1.40 (+2.46%) ▲|BKNG182.65+4.41 (+2.48%) ▲|BLK985.83+24.27 (+2.52%) ▲|BMY56.58-1.04 (-1.81%) ▼|BNY146.43+1.82 (+1.26%) ▲|BRK-B501.32+0.93 (+0.19%) ▲|C140.53+0.57 (+0.41%) ▲|CAT995.21-69.69 (-6.54%) ▼|CL92.40+0.72 (+0.78%) ▲|CMCSA23.74-0.82 (-3.32%) ▼|COF204.58+3.96 (+1.97%) ▲|COP103.35-0.61 (-0.58%) ▼|COST923.50-11.97 (-1.28%) ▼|CRM163.73+7.07 (+4.51%) ▲|CSCO116.84-0.62 (-0.53%) ▼|CVS104.72+1.27 (+1.23%) ▲|CVX165.50-0.26 (-0.16%) ▼|DE630.74-3.59 (-0.57%) ▼|DHR193.93+3.45 (+1.81%) ▲|DIS95.92-0.33 (-0.34%) ▼|DUK125.75-0.83 (-0.66%) ▼|EMR140.02-3.14 (-2.19%) ▼|FDX313.91+0.78 (+0.25%) ▲|GD363.33+9.09 (+2.57%) ▲|GE374.49+0.76 (+0.20%) ▲|GEV1,132.37-42.49 (-3.62%) ▼|GILD126.22-0.12 (-0.10%) ▼|GM75.58-1.50 (-1.95%) ▼|GOOG357.81+4.48 (+1.27%) ▲|GOOGL361.01+3.64 (+1.02%) ▲|GS1,021.36+9.99 (+0.99%) ▲|HD351.43-1.26 (-0.36%) ▼|HON221.77-2.13 (-0.95%) ▼|IBM287.23+6.02 (+2.14%) ▲|INTC127.45-12.18 (-8.72%) ▼|INTU268.67+7.67 (+2.94%) ▲|ISRG400.93+3.25 (+0.82%) ▲|JNJ253.86-0.11 (-0.04%) ▼|JPM333.59+6.26 (+1.91%) ▲|KO81.18-0.09 (-0.11%) ▼|LIN533.18+14.24 (+2.74%) ▲|LLY1,193.00-6.43 (-0.54%) ▼|LMT521.83+12.37 (+2.43%) ▲|LOW221.90+1.41 (+0.64%) ▲|LRCX390.26-43.08 (-9.94%) ▼|MA523.26+9.66 (+1.88%) ▲|MCD269.55-0.76 (-0.28%) ▼|MDLZ58.89+1.05 (+1.82%) ▲|MDT79.26+1.03 (+1.32%) ▲|META612.70+49.41 (+8.77%) ▲|MMM160.51-1.40 (-0.86%) ▼|MO71.38-0.58 (-0.80%) ▼|MRK125.68-2.83 (-2.20%) ▼|MS211.86+2.82 (+1.35%) ▲|MSFT383.80+10.78 (+2.89%) ▲|MU1,047.70-106.59 (-9.23%) ▼|NEE86.66-1.11 (-1.26%) ▼|NFLX74.04+2.64 (+3.69%) ▲|NKE42.93+1.88 (+4.57%) ▲|NOW106.08+6.80 (+6.84%) ▲|NVDA197.97-2.12 (-1.06%) ▼|ORCL143.09-3.46 (-2.36%) ▼|PEP140.51+5.11 (+3.77%) ▲|PFE23.88-0.20 (-0.83%) ▼|PG147.05+0.41 (+0.28%) ▲|PLTR126.08+9.41 (+8.07%) ▲|PM177.08-3.83 (-2.12%) ▼|QCOM183.54-1.25 (-0.68%) ▼|RTX191.21+1.48 (+0.78%) ▲|SBUX102.63+0.44 (+0.43%) ▲|SCHW95.91+3.64 (+3.94%) ▲|SO95.32-0.39 (-0.41%) ▼|SPG222.55-1.11 (-0.49%) ▼|T20.40-0.30 (-1.45%) ▼|TMO514.50+13.14 (+2.62%) ▲|TMUS172.78+5.05 (+3.01%) ▲|TSLA425.70+5.10 (+1.21%) ▲|TXN299.34+1.27 (+0.43%) ▲|UBER72.78+0.62 (+0.85%) ▲|UNH427.38+11.75 (+2.83%) ▲|UNP277.01+5.01 (+1.84%) ▲|UPS109.74+2.24 (+2.08%) ▲|USB62.01+1.61 (+2.66%) ▲|V350.40+7.31 (+2.13%) ▲|VZ41.76-0.58 (-1.37%) ▼|WFC85.69+3.05 (+3.68%) ▲|WMT108.83-4.44 (-3.92%) ▼|XOM135.78-0.94 (-0.69%) ▼|
33.8 C
New York
Wednesday, July 1, 2026

Tag: stage

newssourceFORcompanyinformationcontent1releasesmarket

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been...

Instructure and OpenAI Announce Global Partnership to Embed AI Learning Experiences within Canvas

First-of-its-kind integration transforms education by embedding OpenAI's technology directly within the Canvas learning environment, empowering educators and amplifying student potential SALT LAKE CITY and SAN...

Instructure and OpenAI Announce Global Partnership to Embed AI Learning Experiences within Canvas

First-of-its-kind integration transforms education by embedding OpenAI's technology directly within the Canvas learning environment, empowering educators and amplifying student potential SALT LAKE CITY and SAN...

Orla Mining Reports Pit Wall Event at Camino Rojo

VANCOUVER, BC, July 23, 2025 /CNW/ - Orla Mining Ltd. (TSX: OLA; NYSE: ORLA) ("Orla" or the "Company") reports that an uncontrolled material movement...

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the “Existing Warrants”) to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted exercise prices of $1.40 and were issued by the Company on May 10, 2022; February 1, 2024; May 6, 2024; and December 13, 2024, with each exercise occurring at a reduced exercise price of $0.9047 per share.

Children’s Miracle Network Hospitals’ Ignite: Inspiring This Generation to Lift Up the Next Through Impactful Leadership

Annual Peer-to-Peer Leadership Conference Unites Student Leaders and Hospital Advisors to Strengthen Dance Marathon Programs Nationwide ST. LOUIS, July 23, 2025 /PRNewswire/ -- Children's Miracle...

Cboe Plans to Cease Japanese Equities Operations

Cboe will maintain presence in Japan for its Global Derivatives and Cboe Data Vantage businessesCHICAGO and TOKYO, July 23, 2025 /PRNewswire/ -- Cboe Global Markets,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

Claudin 18.2-Directed Oncology Therapeutics–A Fast-Growing Market with Blockbuster Potential | DelveInsight

Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering,...

CORE LAB REPORTS SECOND QUARTER 2025 RESULTS

REVENUE OF $130.2 MILLION, UP 5% SEQUENTIALLY AND FLAT YEAR-OVER-YEAROPERATING INCOME OF $15.3 MILLION; EX-ITEMS, $14.5 MILLION, UP OVER 23% SEQUENTIALLY AND DOWN 11%...

SOUTHWEST AIRLINES REPORTS SECOND QUARTER 2025 RESULTS

DALLAS, July 23, 2025 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) (the "Company") today reported its second quarter 2025 financial results and Company highlights: Net...

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering

TELA Bio to Participate in the Canaccord Genuity 45th Annual Growth Conference

MALVERN, Pa., July 23, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in the Canaccord Genuity 45th Annual Growth Conference.

Nuclear Energy Newcomers Electrify Final Day of EnerCom’s 30th Anniversary Energy Investment Conference

Five Nuclear Companies to Present at EnerCom Denver – The Energy Investment Conference Qualified Investors, Analysts and Energy Industry Professionals Can Register at No...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsStage

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers